The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback